What the FDA labels say about taking them together
Ocrelizumab and teriflunomide
Ocrelizumab's FDA label of May 14, 2026 names teriflunomide in its drug interactions section; the teriflunomide label PlainMeds reads does not name ocrelizumab.
Check it at the source: the ocrelizumab FDA label on DailyMed (effective May 14, 2026, Genentech, Inc.); the teriflunomide FDA label on DailyMed (effective February 20, 2026, Genzyme Corporation).
What does the ocrelizumab label say about teriflunomide?
Ocrelizumab label, drug interactionsWhen switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ].
Source: FDA drug label (OCREVUS), Genentech, Inc., effective May 14, 2026 (SPL set 9da42362-3bb5-4b83-b4bb-b59fd4e55f0d), via openFDA; the full label on DailyMed
What does the teriflunomide label say about ocrelizumab?
Teriflunomide's label (effective February 20, 2026) does not name ocrelizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Aubagio), NDA202992 (Sanofi Aventis Us), as published by Genzyme Corporation, effective February 20, 2026 (SPL set 4650d12c-b9c8-4525-b07f-a2d773eca155), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ocrelizumab | Teriflunomide | |
|---|---|---|
| Labeled for | n/a | Multiple sclerosis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.233 per tablet 14 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once